Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Silexion Therapeutics Corp (SLXN)

Silexion Therapeutics doses first patient in SIL204 pancreatic cancer Phase 2/3 trial

Neutral Impact 3 of 5 other Written later

Silexion Therapeutics said it has dosed the first patient worldwide in its Phase 2/3 trial of SIL204 in locally advanced pancreatic cancer, at Tel Aviv Sourasky Medical Center in Israel. The filing says additional sites in Israel and Germany are expected to join in the coming months, and the company refers to preliminary clinical readouts in the near term. The filing reports no financial results, guidance, or financing terms.

Key points

  • First patient dosed at Tel Aviv Sourasky Medical Center (Ichilov); announced September 30, 2026
  • Trial plans an initial safety run-in cohort of approximately 18 patients, then a randomized cohort of approximately 166 patients
  • SIL204 is given with standard chemotherapy versus chemotherapy alone in patients with unresectable Stage 3 locally advanced pancreatic cancer with a confirmed KRAS mutation
  • Additional Israeli and German sites are expected to join in the coming months

The filing

CompanySilexion Therapeutics Corp (SLXN)
Form8-K, current report
Filed with the SECSep 30, 2026, 8:52 AM ET
Accession number0001178913-26-004666

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 30, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.